[1] Yu W, Clyne M, Khoury MJ, Gwinn M. Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics, 2010, 26(1): 145-146.[2] Stearns FW. One hundred years of pleiotropy: a retrospective. Genetics, 2010, 186(3): 767-773.[3] Becker KG. The common variants/multiple disease hypothesis of common complex genetic disorders. Med Hypotheses, 2004, 62(2): 309-317.[4] Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P. Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis, 2012, 27(2): 211-218.[5] Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci USA, 2007, 104(21): 8685-8690.[6] Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T, Rudan I, McKeigue P, Wilson JF, Campbell H. Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet, 2011, 89(5): 607-618.[7] 姚晨, 张敏, 邹金凤, 李红东, 王栋, 朱晶, 郭政. 可识别多种癌症的基因功能模块. 中国科学 C辑: 生命科学, 2009, 39(11): 1092-1096.[8] Gu X. Evolutionary framework for protein sequence evolution and gene pleiotropy. Genetics, 2007, 175(4): 1813-1822.[9] 朱晶, 沈晓沛, 肖会, 张杨, 王靖, 郭政. 基于共进化基因功能模块发现候选癌基因. 遗传, 2010, 32(7): 694-700.[10] Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucl Acids Res, 2003, 31(4): e15.[11] Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 2004, 20(3): 307-315.[12] Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 2004, 3(1): Article3.[13] Tanay A, Sharan R, Kupiec M, Shamir R. Revealing modularity and organization in the yeast molecular network by integrated analysis of highly heterogeneous genomewide data. Proc Natl Acad Sci USA, 2004, 101(9): 2981-2986.[14] Tanay A, Sharan R, Shamir R. Discovering statistically significant biclusters in gene expression data. Bioinformatics, 2002, 18(Suppl. 1): S136-S144.[15] Shamir R, Maron-Katz A, Tanay A, Linhart C, Steinfeld I, Sharan R, Shiloh Y, Elkon R. EXPANDER-an integrative program suite for microarray data analysis. BMC Bioinformatics, 2005, 6: 232, doi: 10.1186/1471-2105-6-232.[16] Li WT, Wang R, Bai LF, Yan ZM, Sun ZR. Cancer core modules identification through genomic and transcriptomic changes correlation detection at network level. BMC Syst Biol, 2012, 6: 64, doi: 10.1186/1752-0509-6-64.[17] Yu Y, Feng YM. The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer, 2010, 116(22): 5150-5160.[18] Liu ZJ, Ling K, Wu X, Cao J, Liu B, Li SY, Si Q, Cai Y, Yan C, Zhang Y, Weng YG. Reduced expression of cenp-e in human hepatocellular carcinoma. J Exp Clin Cancer Res, 2009, 28: 156, doi:10.1186/1756-9966-28-156.[19] Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med, 2011, 15(3): 501-513.[20] Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer, 2012, 131(4): 911-923.[21] Wolkersdorfer T, Füssel M, Kiesslich T, Neureiter D, Berr F, Aust D, Wolkersdorfer GW. MHC class II genotype- and MHC class I and II phenotype-related parameters in sporadic colorectal cancer. Oncol Rep, 2011, 26(5): 1165-1171. |